Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants

Susanna Esposito, Lorenza Pugni, Samantha Bosis, Alice Proto, Laura Cesati, Ciro Bianchi, Carolyn Cimino, Fabio Mosca, Nicola Principi

Research output: Contribution to journalArticlepeer-review

Abstract

We assessed the immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine (PCV7) administered three, five and 11 months post-natally to 46 pre-term (PT) and 46 full-term (FT) infants. After each dose, there was no significant difference between the groups in antibody levels for any of the vaccine serotypes. After the second dose, the majority of subjects in both groups showed titres of ≥0.35 μg/mL, whereas an antibody concentration of ≥1.0 μg/mL was usually reached in both PT and FT infants after the third dose. Safety and tolerability was also similar in the groups. These findings support the use of the simplified schedule that includes three doses of PCV7 in both PT and FT infants, and suggest that this may reduce costs, as well as problems related to vaccine supply and administration

Original languageEnglish
Pages (from-to)1703-1708
Number of pages6
JournalVaccine
Volume23
Issue number14
DOIs
Publication statusPublished - Feb 25 2005

Keywords

  • Pneumococcal conjugate vaccine
  • Pre-term infants
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint

Dive into the research topics of 'Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants'. Together they form a unique fingerprint.

Cite this